ECO 2026: gut hormone signals differ in T1D with obesity

The Satiety Gap: Why Obesity in Type 1 Diabetes is a Different Beast

For years, the medical community has largely viewed obesity through a single lens: a metabolic dysfunction often linked to insulin resistance and Type 2 Diabetes (T2D). But new evidence is emerging that suggests we’ve been oversimplifying the narrative. For those living with Type 1 Diabetes (T1D), the battle with the scale isn’t just about calories in versus calories out—it’s about a fundamentally different biological blueprint.

Recent observations from the European Congress on Obesity (ECO) have highlighted a critical discrepancy in gut hormone signaling. Specifically, the “satiety hormone” known as Peptide YY (PYY) appears to be significantly lower in people with T1D, regardless of whether they are lean or living with obesity. This suggests that the feeling of fullness—the biological “stop” sign during a meal—is dampened by the disease itself, not just by excess weight.

Beyond the Scale: The Failure of ‘One-Size-Fits-All’ Weight Loss

The current gold rush in obesity pharmacotherapy—led by GLP-1 receptor agonists like semaglutide and tirzepatide—has seen staggering success in T2D and general obesity populations. However, the T1D community has remained largely in the shadows of these clinical trials. This “evidence gap” is a problem because the metabolic machinery of T1D is distinct.

In T2D, the goal is often to restore insulin sensitivity. In T1D, the challenge is a balancing act between exogenous insulin, glycemic variability, and appetite regulation. When we apply the same weight-loss logic to T1D, we risk ignoring the unique role of hormones like ghrelin (the hunger hormone), which behaves differently in T1D patients than in the general population.

For instance, while ghrelin typically drops as weight increases in the general population, this pattern is disrupted in T1D. This biological “mismatch” means that a drug designed for a T2D patient might not address the root cause of hunger for someone with T1D.

The Shift Toward Precision Metabolic Medicine

The future of obesity treatment is moving toward precision pharmacotherapy. Instead of prescribing a blockbuster drug based on BMI, clinicians will likely use hormone profiling to determine the specific deficit. If a T1D patient shows a profound PYY deficiency, a multi-agonist therapy that specifically targets PYY and GLP-1 receptors would be far more effective than a standard GLP-1 alone.

We are seeing a trend toward “poly-agonists”—drugs that hit three or four different hormone receptors simultaneously. This approach mimics the complex synergy of the gut-brain axis more closely than single-target drugs, offering a lifeline to those whose metabolic signals are profoundly altered by T1D.

Redefining Success: New Endpoints for T1D Care

If the biology is different, the metrics for success must change. For too long, “success” in obesity trials has been defined by a percentage of total body weight loss. But for a person with T1D, weight loss is only one piece of the puzzle. Future trends suggest a shift toward holistic metabolic endpoints, including:

• Satiety Scores: Using patient-reported outcomes to measure if the “hunger noise” has actually decreased.
• Insulin Efficiency: Measuring whether weight loss leads to a reduction in daily insulin requirements.
• Hypoglycemia Frequency: Ensuring that appetite suppressants don’t inadvertently increase the risk of dangerous blood sugar drops.
• Post-Prandial Hormone Response: Analyzing how hormones react after a meal, rather than just fasting levels.

By shifting the focus from the scale to the system, healthcare providers can create a more sustainable and safer path to health for T1D patients. You can read more about current T1D management guidelines to see how these new insights fit into existing care.

The Strategic Opportunity for Pharma and Biotech

From a market perspective, the “T1D with obesity” segment is an underserved frontier. Most pharmaceutical companies have focused on the massive T2D market, leaving a significant gap in data for T1D. The companies that move first to generate high-quality, dedicated evidence in this population will likely dominate the next era of precision obesity care.

This isn’t just about expanding a label; it’s about differentiation. By proving that a specific therapy works for the unique hormonal profile of T1D, a company can move from being a “me-too” weight loss drug to a specialized medical necessity. This will be pivotal in payer negotiations and gaining the confidence of Key Opinion Leaders (KOLs) in the endocrinology space.

FAQ: Obesity and Type 1 Diabetes